1 Department Of Pharmacy Practice, Srm College Of Pharmacy, Faculty Of Medicine And Health Sciences, Srm Institute Of Science & Technology, Kattankulathur, Chengalpattu, Tamil Nadu, India-603203.
Correspondence: Dr. Sarumathy Sundararajan, Associate Professor, Department Of Pharmacy Practice, Srm College Of Pharmacy, Faculty Of Medicine And Health Sciences, Srm Institute Of Science & Technology, Kattankulathur, Chengalpattu, Tamil Nadu, India-603203. Email: sarumats@srmist.edu.in
Background: Covid-19 recovery in patients with diabetes mellitus is frequently associated with persistent metabolic disturbances, increased treatment complexity, impaired health-related quality of life (hrqol), and elevated healthcare costs. Pharmaceutical care interventions may play a crucial role in optimizing post-covid diabetes management by improving clinical outcomes, enhancing quality of life, and reducing economic burden.
Objective: To evaluate the association of pharmaceutical care intervention with glycemic control, health-related quality of life, and treatment costs among covid-19 recovered patients with diabetes mellitus and comorbidities.
Methods: A single-arm interventional study was conducted over 18 months (december 2022 to may 2024) at a tertiary care hospital. A total of 350 covid-19 recovered patients with type 2 diabetes mellitus and associated comorbidities were enrolled. Clinical parameters, including glycemic indices, lipid profile, inflammatory markers, and renal function, were assessed at baseline and follow-up. Hrqol was evaluated using the world health organization quality of life–bref (whoqol-bref) questionnaire. Pharmacoeconomical outcomes were analyzed by comparing direct and indirect healthcare costs before and after pharmaceutical care intervention. Statistical analysis was performed using paired tests, with p < 0.05 considered statistically significant.
Results: A statistically significant reduction in hba1c levels was observed at follow-up compared to baseline (p = 0.0493), indicating improved glycemic control. Other clinical parameters remained stable during the study period. Hrqol scores demonstrated significant improvement across all four whoqol-bref domains, including physical, psychological, social, and environmental health (p < 0.001 for all). Pharmacoeconomical analysis revealed a reduction of 19% in total direct costs, 29% in indirect costs, and an overall 21% decrease in total healthcare expenditure following pharmaceutical care intervention.
Conclusion: Pharmaceutical care intervention was significantly associated with improved glycemic control, enhanced health-related quality of life, and reduced treatment costs among covid-19 recovered patients with diabetes mellitus.
Keywords: Covid-19, Pharmaceutical Care, Diabetes Mellitus, Health-Related Quality Of Life, Pharmacoeconomics, Glycemic Control.
How To Cite This Article: Akari S, Sundararajan S. Association Of Pharmaceutical Care Intervention With Glycemic Control, Health-Related Quality Of Life, And Treatment Costs Among Covid-19 Recovered Patients With Diabetes Mellitus. Int J Drug Deliv Technol. 2026;16(4):466-472. Doi: 10.25258/ijddt.16.4.46